



Orion Interim Report January—March 2015

29 April 2015

Timo Lappalainen
President & CEO

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.


These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

Year started strongly

- Net sales were slightly higher and operating profit clearly higher than in comparative period
- Generic competition to Stalevo started to extend in Europe, but Proprietary Products sales as a whole remained steady due to strong growth in sales of the Easyhaler product family and Dexdor
- Sales grew well in the other business divisions
- Clinical development pipeline strengthened by two new projects
- Outlook estimate for 2015 was updated after the review period




Net sales and operating profit



Breakdown of net sales


Group's net sales in Q1/2015 were EUR 260 million

By business division



- Proprietary Products
- Specialty Products
- Animal Health
- Fermion
- Contract manufacturing & other
- Orion Diagnostica

By market area




- Finland
- Scandinavia
- Other Europe
- North America
- Other countries



Business Reviews

Pharmaceuticals business



Net sales split

EUR million	Q1/15	Q1/14	Change %
Proprietary Products	89	88	+1%
Specialty Products	109	102	+6%
Animal Health	22	15	+40%
Fermion	15	15	-1%
Contract manufacturing & other	10	9	+16%

- Net sales of branded Parkinson's drugs down by 10%, and accounted for 17% of segment's net sales
- Net sales excluding Parkinson's drugs and milestone payments up by 8%
- Animal sedatives and a payment related to sale of product rights drove growth in Animal Health

Best-selling pharmaceuticals Q1/2015

	Net sales, EUR million		2014
Stalevo®, Comtess® & Comtan® (Parkinson's disease)	42	-10%	169
Simdax® (acute decompensated heart failure)	13	+19%	47
Easyhaler® product family (asthma, COPD)	12	+59%	35
dexdor® (intensive care sedative)	11	+40%	35
Dexdomitor®, Domitor®, Domosedan® & Antisedan® (animal sedatives)	7	+42%	25
Generic entacapone products (Parkinson's disease)	6	-9%	26
Burana® (inflammatory pain)	6	+1%	23
Marevan® (anticoagulant)	5	+3%	17
Precedex® (intensive care sedative)	5	-49%	30
Divina® range (menopausal symptoms)	4	+24%	15
Total	45% of pharmaceuticals net sales		110

Products based on Orion's inventions in blue font

Orion clear market leader in Finland


Finnish human pharmaceuticals market in Q1/2015

- Wholesale EUR 521 million (+2%)

Orion in Finnish human pharmaceuticals market

- Sales growth +7%
- Orion clear market leader
 - Market share 12%
- Orion especially strong in self-care products and substitutable prescription drugs

Finland's biggest pharmaceutical companies in Q1/2015



Review of Parkinson's drugs markets

Overall markets for Parkinson's drugs

USD / EUR million		2014	2013	Change %
USA	USD	816	765	+7%
EU TOP 5	EUR	992	985	+1%
Japan	EUR	507	495	+2%

Source: IMS Health sales statistics MAT12/2014

Sales of Orion's branded Parkinson's drugs

USD / EUR million		2014	2013	Change %
USA	USD	17	31	-45%
EU TOP 5	EUR	123	130	-5%
Japan	EUR	54	55	-2%

Source: IMS Health sales statistics MAT12/2014

Market shares of Orion's branded Parkinson's drugs

	2014	2013
Finland ²⁾	20%	22%
Sweden ²⁾	14%	15%
Norway ²⁾	15%	16%
Denmark ²⁾	13%	16%
Germany ³⁾	13%	15%
UK ³⁾	12%	13%
United States ^{3) 4)}	2%	4%
Japan ^{2) 4)}	11%	11%

¹⁾ Germany, UK, France, Spain and Italy


²⁾ including sales to hospitals and retail distributors

³⁾ sales to retail distributors only

⁴⁾ Novartis sales area

dexdor[®] intensive care sedative


European sedative market MAT12/2014*
Total market value EUR 509 million (+3%)



- Propofol EUR 342 million (+3%)
- Midazolam EUR 76 million (-3%)
- Dexmedetomidine EUR 28 million (+28%)
- Remifentanyl EUR 63 million (+4%)

*Source: IMS Health sales statistics MAT12/2014

Dexdor sales



Key clinical pharmaceutical development projects 1 / 2

Project	Indication	PHASE			Registration
Bufomix Easyhaler® (budesonide-formoterol) ¹⁾	Asthma, COPD	I	II	III	
Easyhaler® salmeterol-fluticasone	Asthma, COPD	I	II	III	
ODM-201 (androgen receptor inhibitor) ²⁾	Prostate cancer	I	II	III	
Levosimendan ³⁾	Low Cardiac Output Syndrome	I	II	III	
ORM-12741 (alpha-2c adrenoceptor antagonist) ⁴⁾	Alzheimer's disease	I	IIa		
Dexmedetomidine (intranasal) ⁵⁾	Treatment of pain	I	IIb		
ODM-109 (oral levosimendan)	ALS	I	II		

¹⁾ Aim is to obtain marketing authorisation for product in at least some European countries not included in decentralised marketing authorisation application process.

²⁾ In collaboration with Bayer ³⁾ Partner: Tenax Therapeutics, Inc.

⁴⁾ In collaboration with Janssen Pharmaceuticals ⁵⁾ Partner: Recro Pharma, Inc.

	= Phase completed
	= Phase ongoing
	= New project

More info at: <http://www.orion.fi/en/rd/orion-rd/pipeline/>


Key clinical pharmaceutical development projects 2/2

Project	Indication	PHASE			Registration
ODM-104 (more effective COMT inhibitor)	Parkinson's disease	I			
ODM-203 (targeted FGFR+VEGFR inhibitor)	Solid tumours	I			
ODM-204 (CYP17 enzyme and androgen receptor inhibitor)	Prostate cancer	I			
ODM-106 (GABA-B receptor positive allosteric modulator)	Essential tremor	I			
ODM-108 (negative allosteric modulator of TRPA1 ion channel)	Neuropathic pain	I			

-  = Phase completed
-  = Phase ongoing
-  = New project

More info at: <http://www.orion.fi/en/rd/orion-rd/pipeline/>

Diagnostics business



- Operating profit growth mainly due to exchange rate changes and favourable margin structure of sales from portfolio
- QuikRead® tests remained the main product
- Launching of the first Orion GenRead® test system products continued

Outlook for 2015 (updated on 24 April 2015)

Net sales	Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014).
Operating profit	Operating profit is estimated to exceed EUR 230 million.
Group's capital expenditure	The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions (the Group's capital expenditure was EUR 57 million in 2014).

Orion Calendar 2015

Capital Markets Day for analysts, institutional investors and media in Helsinki	26 May 2015
Interim Report January—June 2015	28 July 2015
Interim Report January—September 2015	27 October 2015



ORION

ORION
Building well-being

Orion's financial objectives

Increasing net sales.

Achievement of this objective requires continuous investment in development of the product portfolio.




Maintaining profitability at a good level.

The aim is operating profit that exceeds 20% of net sales.

Keeping the equity ratio at least 50%.

Distributing an annual dividend that in the next few years will be at least EUR 1.20 per share, and increasing the dividend in the long term.

Key figures by quarter



Key figures for 2011–Q1/2015

Orion's key figures	2011	2012	2013	2014	Q1/2015	Q1/2014	Change %
Net sales, EUR million	917.9	980.4	1,006.9	1,015.3	259.9	245.0	+6.1%
Operating profit, EUR million	282.9	278.3	267.7	272.4	83.1	67.4	+23.3%
Profit before taxes, EUR million	282.0	276.6	264.0	267.8	82.7	66.5	+24.4%
R&D expenses, EUR million	87.5	105.8	101.9	106.2	25.1	26.3	-4.6%
Equity ratio, %	64.2%	61.0%	53.6%	52.3%	38.1%	38.9%	
Gearing, %	-6.9%	-1.7%	8.4%	-4.7%	-20.3%	-0.1%	
ROCE (before taxes), %	49.4%	45.9%	38.5%	36.6%	50.4%	38.9%	
Return on equity, %	43.3%	41.0%	40.3%	41.1%	57.4%	46.5%	
Basic earnings per share, EUR	1.49	1.47	1.46	1.50	0.47	0.37	+24.8%
Cash flow per share before financial items, EUR	1.10	1.23	1.02	1.72	0.38	0.30	+24.3%
Dividend per share, EUR	1.30	1.30	1.25	1.30			
Capital repayment per share, EUR	0.12						

Income Statement 2011–Q1/2015

Formation of profits, EUR million	2011	2012	2013	2014	Q1/2015	Q1/2014	Change %
Net sales	917.9	980.4	1,006.9	1,015.3	259.9	245.0	+6.1%
Cost of goods sold	-305.1	-350.8	-393.5	-401.7	-91.4	-95.8	-4.6%
Gross profit	612.8	629.6	613.4	613.6	168.5	149.2	+13.0%
Other operating income and expenses	3.0	6.3	5.6	1.7	-2.2	0.2	
Sales and marketing expenses	-204.8	-206.1	-204.9	-193.4	-46.6	-46.3	+0.6%
R&D expenses	-87.5	-105.8	-101.9	-106.2	-25.1	-26.3	-4.6%
Administrative expenses	-40.6	-45.7	-44.5	-43.3	-11.5	-9.4	+23.2%
Operating profit	282.9	278.3	267.7	272.4	83.1	67.4	+23.3%
Profit before taxes	282.0	276.6	264.0	267.8	82.7	66.5	+24.4%
Profit for the period	209.5	206.9	206.2	211.3	65.7	52.6	+24.9%

Product protection situation of key products

Key patents or data protection expire

Molecule	Product	Indication	Key patents or data protection expire		
			Europe	USA	Japan
Entacapone	Stalevo [®] , Comtess [®] and Comtan [®]	Parkinson's disease	November 2012 October 2013 ¹⁾	October 2013	January 2015 ²⁾
Levosimendan	Simdax [®]	Acute decompensated heart failure	September 2015	Not marketed	Not marketed
Dexmedetomidine	Precedex [®] <i>dexdor</i> [®]	Intensive care sedative	July 2013 September 2021 ³⁾	January 2014 ⁴⁾	June 2012

¹⁾ Stalevo data protection expired


²⁾ Data protection of Comtan expired

³⁾ Dexdor data protection expires

⁴⁾ Six months paediatric exclusivity granted for Precedex in the United States expired

Dividend distribution policy

Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives.





ORION

ORION
Building well-being